MMJ’s core business is holding minority investments across along the cannabis value-chain in Australia, Canada and Europe.
() investee Embark Heath has been granted an amendment to its Health Canada licence allowing direct sales of cannabis extracts, cannabis topicals and edible cannabis products from the Embark Delta Inc facility in Delta, British Columbia.
The amendment permits sales of Cannabis 2.0 products directly to Canadian provinces & territories and allows Embark Delta to further expand its existing and future product offerings to the medical and recreational consumer markets with concentrates, extracts and nano-emulsified topical and edible products.
In addition, Embark can now offer white-labelling turn-key manufacturing services to its commercial accounts.
Embark is currently producing Bubble Hash, Dry Sift, Traditional Pressed Hash and Rosin at the Delta facility.
“Another key milestone”
“Receiving our sales licence to allow for the sale of extracts and concentrates in conjunction with EmbarkNano topicals, edibles and beverages is another key milestone in Embark’s path to growth and profitability,” said Embark’s CEO Dr Luc C Duchesne.
“The Embark portfolio of products addresses the evolving needs of today’s consumer.”
Upcoming product launches
Embark will bring products to market under the Embark Brands portfolio in order to meet…
